Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460408
Status:
COMPLETED
Last Update Posted:
2012-12-11
First Post:
2007-04-13
Brief Title:
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
European Epidemiologic COHORT Study A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration AMD In Europe
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections The Committee for Medicinal Products for Human Use CHMP is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular wet age-related macular degeneration AMD The study will provide information about physician practice patterns and characteristics of patients treated with Macugen
Detailed Description:
No comparator Patients with age-related macular degeneration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None